• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific reports $1.6 billion first-quarter loss

Boston Scientific reports $1.6 billion first-quarter loss

April 27, 2010 By MassDevice staff

A self-imposed hold on two of its best-selling defibrillators last month helped rip a $1.8 billion hole in the bottom line at Boston Scientific Corp. (NYSE:BSX) during the first three months of 2010.

The company also said that the month-long suspension of U.S. sales for its Cognis and Teligen defibrillators could result in as much as $500 million in lost sales during 2010 and reduce adjusted earnings this year by at least $180 million.

The Natick, Mass.-based medical device colossus late Monday announced a net loss of $1.6 billion, or $1.05 a share, on $1.96 billion in sales for the January-to-March fiscal period. The results include a $1.85 billion write-down of goodwill connected with its cardiac rhythm management division and $65 million in restructuring costs, which eventually will see the CRM and the cardiovascular operations at Boston Scientific merged into a single unit.

Company officials are scheduled to discuss the quarter and their outlook for the rest of 2010 in a conference call beginning at 8 a.m. April 27.

In prepared remarks, CEO Ray Elliott said the hold on Cognis and Teligen sales that began March 15 had an obvious effect on both revenues and net income. Overall, the CRM unit recorded $538 million in first-quarter sales, down from $589 million a year ago and due almost entirely to a $66 million drop in comparable U.S. sales of implantable cardiac defibrillators during the latest period.

The company voluntarily stopped all ICD shipments and pulled its inventory from the field after discovering that it had failed to properly notify U.S. regulators of changes to its manufacturing process and added a new parts supplier for the Cognis, Teligen and similar product lines. Sales resumed April 15.

Boston Scientific officials also sharply reduced their estimates for sales and earnings from prior guidance released in February. They said they now expect full-year revenues of between $7.6 billion to $8 billion, down from the previous range of $8.1 billion to $8.5 billion. Adjusted earnings — which do not include goodwill write-downs, amortization, restructuring and asset impairment charges — likely will be off about 12 cents per share, to a new range of between 50 cents and 60 cents per share.

The net loss for the year, they said, should be between $1.3 billion to $1.5 billion, or between 88 cents and $1 per share. The firm earlier had been expecting a profit as high as $740 million in 2010.

Separately, the company said that chief technology officer Fredericus Colen plans to retire effective June 30. Colen, 57, was head of the CRM unit over a nine-month span ending in February, when he was promoted to the CTO post.

Colen joined Boston Scientific in 1999 and held a variety of management positions. The regulatory filing cited “family reasons” for his decision to retire. No replacement was immediately named.

Filed Under: Business/Financial News, MassDevice Earnings Roundup, News Well Tagged With: 2010, Boston Scientific

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy